Cite

    Armstrong, A. et al. (2017). Clinical outcomes and survival surrogacy studies of prostate‐specific antigen declines following enzalutamide in men with metastatic castration‐resistant prostate cancer previously treated with docetaxel. Cancer. 123 (12), pp. 2303-2311. [Online].